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ABSTRACT
Hepatitis B virus (HBV) is the leading cause of viral hepatitis, as currently over 2 billion people have HBV infection worldwide. Nucleic 
acid assay and quantitative hepatitis B surface antigen (HBsAg) have been developed for diagnostic and therapeutic monitoring of patients 
with HBV infection. These tests might also show correlation between HBV DNA and HBs serostatus. The study aimed to find and analyze 
the frequency and impact of HBsAg seropositivity among patients revealed HBV DNA negative level through quantitative estimation of 
both seromarkers. Real-time polymerase chain reaction (RT-PCR) and Elecsys assays were used for quantitative estimation of HBV DNA 
and HBs antigen, respectively. A total of 256 blood samples were used from patients referred for either diagnostic purpose and/or HBV 
viral load monitoring after antiviral therapy. Blood profile analysis showed 12.26% HBs antigen seropositivity among patients revealed 
negative for nucleic acid assay for HBV DNA. Positive HBs antigen titers ranged from 1000–50,000 COI, with seronegative anti-HBs 
antibody test for all samples tested positive for HBs antigen. This study delineated that negative or undetectable quantitation of HBV 
DNA level does not exclude HBV infection; as the level might fluctuate in different phases of HBV replication. This gives an impression 
and raising a question about significance of replacing test for HBsAg with quantitation of HBV DNA PCR assay. Thus, the study refers to 
a special HBV profile outside the classical pattern.
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INTRODUCTION
Hepatitis B virus (HBV) is the leading cause of viral hepatitis, as currently over 2 billion people have HBV infection worldwide. Approximately 600,000 
deaths occur every year as a result of the acute and chronic 
consequences of HBV infection.[1] Chronic HBV affects nearly 
350 million patients worldwide and may further progress to 
cirrhosis and/or hepatocellular carcinoma (HCC) in 15–40% 
of cases.[2] HBV infection is a dynamic process characterized 
by replicative and non-replicative phases based on virus-host 
interaction, which are present in some form of all infected 
patients.[3] To measure HBV DNA (viral load), a laboratory 
measures how many HBV DNA units are found in 1 ml of blood. 
The result is written in international units per ml (IU/ml). High 
levels of HBV DNA indicate a high rate of HBV replication; 
however, low or undetectable levels–<2000 IU/ml indicate an 
“inactive” infection.[4] During HBV infection, markers can be 
detected in sera samples using immunoassays. For example, 
patient sera that contain anti-HBs indicates immunity from 
past infections or vaccinations, and a patient with anti-HBe 
antibodies in their sera is considered as spontaneous resolution 
of infection or therapy-induced improvement.[5,6] One of the 
serological methods using for the diagnosis of HBV is enzyme 
immune assays. The hepatitis B surface antigen (HBsAg) 
and HBV DNA levels were considered to be a risk factor of 
hepatocarcinogenesis in untreated HB patients.[7] The levels 
of quantified HBsAg are considered as a marker with which 
to evaluate the host immunological control of infection and 
HBV replication.[8] Low HBsAg levels in some HBV patients 
are considered to indicate a high likelihood of HBV clearance 
and lower hepatitis activity.[7,9] The aim of this study was 
to estimate HBV-DNA positivity states among serologically 
screened patients and to compare the sensitivity of molecular 
and serological methods for the diagnosis of HBV infections.
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MATERIALS AND METHODS
For this cross-sectional study, a total of 256 blood samples were 
collected from HBV patients referred to Erbil Central Laboratory, 
from June 2017 to September 2017. Both sexes were included 
(154 males and 102 females), with age range between 20 and 
60 years. Real-time polymerase chain reaction (RT-PCR) as a 
molecular and Elecsys assay as a serological method were used 
for the diagnosis and comparing their sensitivity purposes. For 
RT-PCR technique, 5 ml of venous blood were collected using 
EDTA tubes and centrifuged at 1000 rpm for 5 min and patients’ 
plasma was separated. Viral DNA was extracted from a 200 µl 
aliquot of serum using a Qiagen mini blood kit (Qiagen, Hilden, 
Germany) according to the manufacture instructions. Viral 
loads of HBV DNA were estimated by RT-PCR (HBV RG PCR 
artus, Germany). The amplification was performed in a 50 µl 
reaction mixture containing 30 µl of mixture of HBV RG Master 
mix (buffer, dNTP, primer, probe, and enzymes) and HBV RG 
inhibition control mixed with 20 µl of DNA template to each 
reaction. The primers HBV-Taq I (forward primer): CAA CCT CCA 
ATC ACT CAC CAAC and HBV-Taq 2 (reverse primer): ATA TGA 
TAA AAC GCC GCA GAC AC were used from the sequences of the 
conserved regions of the HBV surface gene used previously by 
Weinberger et al.[10] For performing RT-PCR, Rotorgene 3000 (a 
machine used routinely in Erbil Central Laboratory for detection 
of variety of DNAs and RNAs) was used following manufacture’s 
instructions. The RT-PCR cycling parameters consisted of 
denaturation at 95°C for 15 s, 55°C for 30 s, and 72°C for 15 
s. The results were considered positive if a signal was detected 
in Cycling A FAM, whereas no signal detection indicated as 
negative results. The quantitation of HBV DNA was performed 
for all blood samples and the results were considered positive 
and significant if viral load was more than 1×105 viral copies/
ml. Titers <50 IU were considered as negative for HBV DNA. 
The screened results were categorized according to positive HBV 
DNA titers into inactive, gray zone, and active carriers.
Quantitation of HBsAg was measured using the Elecsys 
HBsAg quantitative assay. Detection of HBsAg by Elecsys 
utilizes a sandwich principle and this assay has two stages: 
First, a complex is formed with two monoclonal HBsAg-
specific antibodies, one of which is biotinylated and the other 
labeled with a ruthenium complex. This complex joins to the 
solid phase through the interaction of biotin and streptavidin 
after the attachment of streptavidin-coated microparticles.[11] 
The mixture is subsequently aspirated into a measuring cell, 
where application of a voltage induces chemiluminescent 
emission, which is measured by a photomultiplier. All serum 
samples were tested at a dilution of 1:400. The Elecsys HBsAg 
quantitative assay is calibrated to give results in IU/ml.[11]
Statistical Analysis
Statistical analysis was done using SPSS 23.0. HBV titers 
expressed as means ± standard error. Comparisons between 
active and inactive carriers use t-tests. Comparisons between 
multiple groups were performed by ANOVA. P ≤ 0.05 was 
considered as statistically significant.
RESULTS AND DISCUSSION
Of the 256 cases, 154 (60%) were male and 102 (40%) were 
female, with age range between 20 and 60 years. RT-PCR 
results showed that 163 of 256 samples were HBV DNA 
negative, from them, 20 samples showed positive results for 
HBsAg quantitation [Table 1].
The Asian Pacific Association for the Study of the Liver, 
European Association for the Study of the Liver, and the 
guidelines of the American Association for the Study of Liver 
Diseases refer that the disappearance of HBsAg is the ideal 
and cornerstone during natural course of HBV infection.[12-14] 
From the clinical standpoint of view, the progression from 
chronic hepatitis B to cirrhosis is increasingly signified through 
the HBV viral load.[8] Meanwhile, quantitative HBsAg level 
was regarded as marker for clearance, hepatitis activity, and 
immunological host response to control HBV replication and 
the likelihood of inactive virus carrier.[9,7,15] However, little is 
known about correlation between HBV replication and low 
levels of HBsAg, as reported in some patients with chronic 
HBV infection.[16-18]
The results of the present study showed 12.26% HBs 
seropositivity (range 1000–5000 COI) among patients 
seronegative for HBV DNA [Table 2], with highly significant 
difference (P ≤ 0.001) between mean of HBV DNA seropositive 
Table 1: Baseline patient’s characteristics




HBV DNA IU/ml 256
<50 (negative) 163 (63.67%)
101–500 22 (24.44%)




qHBsAg tested 163/256 (63.67%)
<10 COI 143 (55.85%)
1000–2000 COI 3 (15%)
2001–3000 COI 4 (20%)
3001–4000 COI 8 (40%)




HBs positive, HBV DNA negative 20/163
qHBsAg: Quantitative hepatitis B surface antigen, HBV: Hepatitis B virus
Table 2: Frequencies of HBV DNA seropositivity among patients 





HBV DNA PCR−ve (n=163)
HBs +ve HBs −ve
n=256 93 (36.32%) 20 (12.26%) 143 (87.73%)
HBV: Hepatitis B virus, PCR: Polymerase chain reaction
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and negative titers [Table 3]. Regarding to the gender 
positivity for PCR test, in total of 154 male patients 65 (42%) 
were positive and of 102 Female patients only 28 (27%) were 
positive [Table 4]. The seromarkers profile among patients 
negative for HBV DNA revealed anti-HBs antibody seronegative 
among the total 20 patients positive for HBsAg [Table 5]. 
However, results of anti-HBs titers among patients negative for 
HBV DNA showed 20 samples were positive showing different 
titers [Table 6]. During the immune-tolerant phase, HBsAg 
level is the highest one, and the level decreases progressively 
from immune tolerance to inactive phase that reflects a low 
replicative phase of immune control.[19] The detection of HBV 
infection is vital for diagnosis our group published a paper that 
delineated the impact of PCR DNA assay for the diagnosis of 
HBV infection.[20]
The data of this study are agree with other studies[21] for 
the serologic profile of HBsAg seropositivity among patients 
screened negative for HBV DNA. They reported 6% of their 
samples gave HBsAg positive among donations negative for 
HBV DNA level, others[8] referred that in nine patients with 
HCC; HBV DNA was undetectable but the level of HBsAg was 
≥2000 COI. Others reported 31.4% HBsAg positive among 
patients negative for HBV DNA.[22] However, data from another 
study showed that 100 of 140 patients were seronegative for 
HBV DNA.[23] Another study[24] reported that 69% of confirmed 
HBsAg-positive donations had undetectable HBV DNA levels. 
However, others[25,26] found that none of the HBsAg-positive 
donors with very low or negative for HBV DNA were anti-HBs 
antibody positive.[24,27]
Among explanation for such unusual HBV serologic 
profile, the patients may be chronically infected with HBV 
particularly; they are in the non-replicative phase as part of 
the natural course of infection.[22] The question might be raised 
here is about such serologic profile of HBsAg positive among 
patients negative for HBV DNA, are these patients infectious 
and transmissible for community,[21] referred for the need of 
larger sample volume (5–10 ml) necessary for extraction and 
concentration to determine the real HBV DNA status among 
samples negative for DNA.
In this study, Pearson’s correlation analysis revealed no 
significant correlation between serum HBV DNA and HBsAg 
levels (r = 0.331; P > 0.3) [Figure 1]. Different studies reported 
discrepant results regarding correlation between HBV DNA and 
HBsAg levels, our data were disagree with other studies who 
reported positive correlation.[28-34] Meanwhile, our results agree 
with others for no correlation between HBV DNA and HBsAg 
levels.[35,36] Such correlation is only weak in patients negative 
for HBsAg.[19,30,37,38] This is because the level of HBV DNA 
fluctuates from undetectable to >2,000,000 IU/ml.[12] This is 
why the level of HBsAg does not fall in the same proportion 
or level when correlated with HBV DNA level as a marker for 
Table 3: Mean titers of HBV DNA among patients screened
Number 
screened






n=256 18,582,661.24±5,934,488.97 31.12±4.45 0.000
HBV: Hepatitis B virus, PCR: Polymerase chain reaction
Figure 1: Pearson correlation between quantitative hepatitis B virus 
DNA level and hepatitis B surface antigen. R = 0.229, P = 0.331
Table 5: HBsAg and anti-HBs seromarkers profile among patients negative for HBV DNA
Serological profile HBs Anti-HBs (n=20)
>10 COI +ve <0.9 COI −ve <10 IU/ml −ve >10 IU/ml +ve
HBV DNA PCR negative (n=163) 20 (12.27%) 143 (87.73%) 20 (100%) 0.00
HBV: Hepatitis B virus, PCR: Polymerase chain reaction, HBsAg: Hepatitis B surface antigen
Table 4: Frequencies of HBV DNA positivity according to the 
gender
Gender Positive PCR Negative 
PCR
Total P-value
Male 65 (42.20%) 89 (57.79%) 154 ≤0.001
Female 28 (27.45%) 74 (72.54%) 102
Total 93 (36.3232%) 163 (63.67%) 256
HBV: Hepatitis B virus, PCR: Polymerase chain reaction
Table 6: Distribution of HBsAg and anti-HBs titers among patients negative for HBV DNA
HBs titers COI Anti-HBsAb IU/ml
Non-reactive <0.9 COI 1000–2000 2001–3000 3001–4000 4001–>5000 Non-reactive <10 Reactive >10
0.00 3 (15%) 4 (20%) 8 (40%) 5 (25%) 20 (100%) 0.00
HBV: Hepatitis B virus, PCR: Polymerase chain reaction, HBsAg: Hepatitis B surface antigen
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disease progression.[4] Martinot-Peignoux et al.[39] referred 
that HBV DNA diminished with time from seroclearance; 
however, covalently closed circular DNA as integrated HBV 
DNA remained detectable in liver biopsies. It is thus critical 
for clinicians to be aware of the significance of HBV DNA serial 
measurement and lifelong follow-up to establish and confirm 
that inactive carrier condition is maintained.[4] Among major 
guidelines, if HBV DNA is undetectable, either prophylaxis 
with lamivudine or strict follow-up every 1–3 months for ALT 
and HBV DNA level is indicated.[13]
CONCLUSION
Serology will undoubtedly continue to be widely used in the 
detection of HBV infection; however, HBV DNA assays can 
serve as an important tool, especially in detecting low levels 
of HBV DNA and in patients with the past HBV infection. 
Data from the present study also concluded that negative or 
undetectable quantitation of HBV DNA level does not exclude 
HBV infection; as the level might fluctuate in different phases 
of HBV replication. This gives an impression and raising a 
question about significance of replacing test for HBsAg with 
quantitation of HBV DNA PCR assay. Thus, the study refers to 
a special HBV profile outside the classical pattern.
REFERENCES
1. World Health Organization. “World Health Organization Hepatitis 
B Factsheet”. Geneva: World Health Organization, 2017.
2. S. Baig, A. A. Siddiqui, W. Ahmed, H. Qureshi and A. Arif. “The 
association of complex liver disorders with HBV genotypes 
prevalent in Pakistan”. Virology Journal, vol. 4, no. 1, p. 128, 2007.
3. G. Fattovich. “Natural history of hepatitis B”. Journal of 
Hepatology, vol. 39, pp. 50-58, 2003.
4. I. Pita, A. M. Horta-Vale, H. Cardoso and G. Macedo. “Hepatitis 
B inactive carriers: An overlooked population?” GE Portuguese 
Journal of Gastroenterology, vol. 21, no. 6, pp. 241-249, 2014.
5. L. M. Villar, H. M. Cruz, J. R. Barbosa, C. S. Bezerra, M. M. Portilho 
and L. de Paula Scalioni. “Update on hepatitis B and C virus 
diagnosis”. World Journal of Virology, vol. 4, no. 4, p. 323, 2015.
6. I. J. Radii and A. M. Saud. “Comparative assessment between 
serological and molecular diagnosis for patients groups with 
hepatitis b virus”. International Journal of Current Microbiology 
and Applied Science, vol. 6, no. 3, pp. 742-748, 2017.
7. T. C. Tseng, C. J. Liu, H. C. Yang, T. H. Su, C. C. Wang, C. L. Chen 
and J. H. Kao. “High levels of hepatitis B surface antigen increase 
risk of hepatocellular carcinoma in patients with low HBV load”. 
Gastroenterology, vol. 142, no. 5, pp. 1140-1149, 2012.
8. M. Kawanaka, K. Nishino, J. Nakamura, T. Oka, N. Urata, D. Goto 
and G. Yamada. “Quantitative levels of hepatitis B virus DNA 
and surface antigen and the risk of hepatocellular carcinoma 
in patients with hepatitis B receiving long-term nucleos (t) ide 
analogue therapy”. Liver Cancer, vol. 3, no. 1, pp. 41-52, 2014.
9. T. C. Tseng, C. J. Liu, T. H. Su, C. C. Wang, C. L. Chen, P. J. Chen 
and J. H. Kao. “Serum hepatitis B surface antigen levels predict 
surface antigen loss in hepatitis B e antigen seroconverts”. 
Gastroenterology, vol. 141, no. 2, pp. 517-525, 2011.
10. K. M. Weinberger, E. Wiedenmann, S. Böhm and W. Jilg. 
“Sensitive and accurate quantitation of hepatitis B virus DNA 
using a kinetic fluorescence detection system (TaqMan PCR)”. 
Journal of Virological Methods, vol. 85, no. 1-2, pp. 75-82, 2000.
11. H. J. Lee, S. Y. Kim, S. M. Lee, J. Heo, H. H. Kim, C. L. Chang 
and H. C. Son. “Elecsys hepatitis B surface antigen quantitative 
assay: Performance evaluation and correlation with hepatitis 
B virus DNA during 96 weeks of follow-up in chronic hepatitis 
B patients”. Annals of Laboratory Medicine, vol. 32, no. 6, 
pp. 420-425, 2012.
12. A. S. Lok and B. J. McMahon. “Chronic hepatitis B: Update 2009”. 
Hepatology, vol. 50, no. 3, pp. 661-662, 2009.
13. European Association for the Study of the Liver. “EASL clinical 
practice guidelines: Management of chronic hepatitis B virus 
infection”. Journal of Hepatology, vol. 57, no. 1, pp. 167-185, 2012.
14. Y. F. Liaw, J. H. Kao, T. Piratvisuth, H. L. Y. Chan, R. N. Chien, 
C. J. Liu and D. Amarapurkar. “Asian-Pacific consensus statement 
on the management of chronic hepatitis B: A 2012 update”. 
Hepatology International, vol. 6, no. 3, pp. 531-561, 2012.
15. H. Lik-Yuen Chan, G. Lai-Hung Wong, C. H. Tse, H. Y. Chan and 
V. Wai-Sun Wong. “Viral determinants of hepatitis b surface 
antigen seroclearance in hepatitis b e antigen-negative chronic 
hepatitis b patients”. Journal of Infectious Diseases, vol. 204, 
no. 3, pp. 408-414, 2011.
16. J. Cheng, C. Sun, Y. Chen, Y. Dai, X. U. Zhiliang, G. Sun and 
L. I. Xiaojun. “Molecular analysis on chronic hepatitis B patients 
with low-level HBsAg”. Chinese Journal of Laboratory Medicine, 
vol. 32, no. 10, pp. 1128-1132, 2009.
17. J. Cheng, C. Sun, Y. Chen, Z. Xu, G. Wang, G. Sun and X. 
Li. “Analysis on clinical features and immunity in chronic hepatitis 
B virus infected patients with low-level HBsAg”. African Journal 
of Microbiology Research, vol. 4, no. 7, pp. 547-550, 2010.
18. A. Jeffery-Smith, J. Hubb, A. Oliver and C. Y. Tong. “An apparent 
low level of hepatitis B surface antigen (HBsAg) in the presence 
of significant viral replication”. Journal of Clinical Virology: 
The Official Publication of the Pan American Society for Clinical 
Virology, vol. 77, p. 111, 2016.
19. T. Nguyen, A. J. Thompson, S. Bowden, C. Croagh, S. Bell, 
P. V Desmond and S. A. Locarnini. “Hepatitis B surface antigen levels 
during the natural history of chronic hepatitis B: A perspective on 
Asia”. Journal of Hepatology, vol. 52, no. 4, pp. 508-513, 2010.
20. S. T. Balaky, S. G. Hussain, A. A. Khaleel, F. T. Sabeer and A. H. Mawlood. 
“Molecular diagnosis in differentiating active and inactive forms of 
hepatitis b virus carriers”. Journal of University of Babylon for Pure and 
Applied Sciences, vol. 26, no. 10, pp. 41-45, 2018.
21. M. C. Kuhns, S. H. Kleinman, A. L. McNamara, B. Rawal, 
S. Glynn and M. P. Busch. “Lack of correlation between HBsAg 
and HBV DNA levels in blood donors who test positive for HBsAg 
and anti-HBc: Implications for future HBV screening policy”. 
Transfusion, vol. 44, no. 9, pp. 1332-1339, 2004.
22. A. S. K. Al-Suraifi, A. D. J. Al-Rubaie, S. M. G. Al-Mayahie and 
N. M. M. Al-Abedy. “Unusual HBV mixed genotype infections 
among hepatitis type B Iraqi patients in Wasit Province/Iraq”. 
International Journal of Biomedical Engineering and Clinical 
Science, vol. 2, no. 1, pp. 1-7, 2016.
23. I. A. A. Khaled, O. M. Mahmoud, A. F. Saleh and E. A. Baioumi. 
“Prevalence of HBV genotypes in Egypt among hepatitis patients”. 
Journal of American Science, vol. 6, no. 11, pp. 185-190, 2010.
24. W. K. Roth, M. Weber, D. Petersen, C. Drosten, S. Buhr, W. Sireis 
and E. Seifried. “NAT for HBV and anti-HBc testing increase 
blood safety”. Transfusion, vol. 42, no. 7, pp. 869-875, 2002.
25. S. Sato, W. Ohhashi, H. Ihara, S. Sakaya, T. Kato and H. Ikeda. 
“Comparison of the sensitivity of NAT using pooled donor samples 
for HBV and that of a serologic HBsAg assay”. Transfusion, 
vol. 41, no. 9, pp. 1107-1113, 2001.
26. H. Hennig, I. Puchta, J. Luhm, P. Schlenke, S. Goerg and 
H. Kirchner. “Frequency and load of hepatitis B virus DNA in first-
time blood donors with antibodies to hepatitis B core antigen”. 
Blood, vol. 100, no. 7, pp. 2637-2641, 2002.
27. M. C. Kuhns, A. L. McNamara and R. Perrillo. “Intermittent PCR 
positivity for hepatitis B viral DNA in surface antigen negative 
anti-core positive individuals”. Transfusion, vol. 39, no. 10, 
pp. 95S-95S, 1999.
28. Y. J. Kim, H. C. Cho, M. S. Choi, J. H. Lee, K. C. Koh, B. C. Yoo and 
S. W. Paik. “The change of the quantitative HBsAg level during 
Khaleel, et al.: Significance of HBV diagnosis by RT-PCR
56 http://journals.cihanuniversity.edu.iq/index.php/cuesj CUESJ 2020, 4 (1): 52-56
the natural course of chronic hepatitis B”. Liver International, 
vol. 31, no. 6, pp. 817-823, 2011.
29. J. Jaroszewicz, B. C. Serrano, K. Wursthorn, K. Deterding, 
J. Schlue, R. Raupach and M. Cornberg. “Hepatitis B surface 
antigen (HBsAg) levels in the natural history of hepatitis B virus 
(HBV)-infection: A European perspective”. Journal of Hepatology, 
vol. 52, no. 4, pp. 514-522, 2010.
30. A. Alghamdi, N. Aref, M. El-Hazmi, W. Al-Hamoudi, K. Alswat, 
A. Helmy and A. A. Abdo. “Correlation between hepatitis B 
surface antigen titers and HBV DNA levels”. Saudi Journal of 
Gastroenterology: Official Journal of the Saudi Gastroenterology 
Association, vol. 19, no. 6, p. 252, 2013.
31. P. P. Primadharsini and I. Wibawa. “Correlation between 
quantitative HBsAg and HBV-DNA in chronic hepatitis B 
infection”. Indonesian Journal of Gastroenterology, Hepatology, 
and Digestive Endoscopy, vol. 14, no. 1, pp. 9-12, 2013.
32. M. Z. Hong, W. Q. Huang, F. Min, J. C. Xu, Z. Lin, K. N. Fang and 
J. S. Pan. “Enhanced HBsAg synthesis correlates with increased 
severity of fibrosis in chronic hepatitis B patients”. PLoS One, 
vol. 9, no. 1, p. e87344, 2014.
33. O. Günal, S. Barut, I. Etikan, F. Duygu, U. Tuncel and M. Sünbül. 
“Relation between serum quantitative HBsAg, ALT and HBV DNA 
levels in HBeAg negative chronic HBV infection”. Turkish Journal 
of Gastroenterology, vol. 25, no. 1, pp. 142-146, 2014.
34. G. Li, J. Wang, Y. Bao, L. Zheng, K. Ge, X. Zhou and G. Chen. 
“Clinical significance of serum HBsAg levels, HBsAg/HBV 
DNA ratio, and association with liver inflammation activity 
in HBeAg-positive chronic hepatitis B”. Zhonghua Gan Zang 
Bing Za Zhi=Zhonghua Ganzangbing Zazhi=Chinese Journal of 
Hepatology, vol. 23, no. 1, pp. 40-45, 2015.
35. A. Ganji, A. Esmaeilzadeh, K. Ghafarzadegan, H. Helalat, 
H. Rafatpanah and A. Mokhtarifar. “Correlation between HBsAg 
quantitative assay results and HBV DNA levels in chronic HBV”. 
Hepatitis Monthly, vol. 11, no. 5, p. 342, 2011.
36. R. M. Mukherjee, J. Arava, P. B. Reddy, P. N. Rao, R. Gupta 
and D. N. Reddy. “Role of hepatitis b virus surface antigen 
quantification in E antigen negative chronic hepatitis B infection”. 
Global Journal of Science Frontier Research, vol. 13, no. 1, pp. 1-5, 
2013.
37. H. Park, J. M. Lee, J. H. Seo, H. S. Kim, S. H. Ahn, D. Y. Kim 
and J. Y. Park. “Predictive value of HBsAg quantification for 
determining the clinical course of genotype C HBeAg-negative 
carriers”. Liver International, vol. 32, no. 5, pp. 796-802, 2012.
38. A. J. Thompson, T. Nguyen, D. Iser, A. Ayres, K. Jackson, 
M. Littlejohn and G. K. Lau. “Serum hepatitis B surface antigen 
and hepatitis B e antigen titers: Disease phase influences 
correlation with viral load and intrahepatic hepatitis B virus 
markers”. Hepatology, vol. 51, no. 6, pp. 1933-1944, 2010.
39. M. Martinot-Peignoux, M. Lapalus, C. Laouénan, O. Lada, 
A. C. F. Netto-Cardoso, N. Boyer and P. Marcellin. “Prediction 
of disease reactivation in asymptomatic hepatitis B e antigen-
negative chronic hepatitis B patients using baseline serum 
measurements of HBsAg and HBV-DNA”. Journal of Clinical 
Virology, vol. 58, no. 2, pp. 401-407, 2013.
